NCT07058779View on ClinicalTrials.gov

Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Safety Issues

Interventions

DRUG

SSS55

SSS55 is an injection targeting complement C3b

All Listed Sponsors

lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY